On January 10, a document titled "Suspension of COVID-19 Project Performance Salary Plan" was circulated online and was signed by Beijing Sinovac Zhongwei Biotechnology Company. It mentioned that all production of the company's COVID-19 vaccines had been suspended and that the company currently has no COVID-19 vaccine products for sale. At noon on January 10, a reporter from Jimu News called the product consultation hotline of Sinovac Biotechnology Co., Ltd. The staff confirmed that Sinovac’s new crown vaccine has indeed been discontinued. If you still need to inject the product, you should ask the local Center for Disease Control and Prevention whether it has stock.
The reporter noticed that there are still a number of vaccines available for injection against new strains in various parts of the country.
The reporter noticed that the above-mentioned plan was signed on January 9 and was stamped with the official seal of Beijing Sinovac Zhongwei Biotechnology Company. It was mentioned that at this stage, the company's new crown vaccine has stopped production and the company currently has no new crown vaccine products for sale. The company has decided to stop paying existing employees' new crown project performance wages from January 2024.
Beijing Sinovac Zhongwei Biotechnology Co., Ltd. is a subsidiary of Sinovac Biotechnology Co., Ltd. At noon on January 10, a reporter called the product consultation hotline of Sinovac Biotechnology Co., Ltd., and the staff confirmed that the company's Sinovac COVID-19 vaccine has indeed been discontinued. If you still need to inject the product, you must ask the local Centers for Disease Control and Prevention whether it is in stock. As for the authenticity of the "suspended performance-based salary plan for COVID-19 projects" reported online, the other party said it was unclear and she was only responsible for product consultation.
The reporter noticed that some manufacturers had previously suspended the production of the new coronavirus vaccine.
In April last year, Shanghai Pharmaceuticals CanSino’s “Low-Cost Operation Notice” spread on the Internet. The content of the notice shows that it has decided to suspend the production line starting from April 4 for a period of 180 days. According to Red Star News' report at the time, staff at CanSino's patient answering hotline said that the COVID-19 (vaccine) production line in Shanghai was temporarily suspended, and there were no problems at the headquarters. The demand for the new coronavirus vaccine is not that big now, so the Shanghai CanSino COVID-19 (vaccine) production line has temporarily stopped production, which will not affect other aspects.
Jimu News reporters learned that there are currently a number of new coronavirus vaccines available for injection in various places. The reporter logged into a vaccination appointment app called "Xiaodou Miao" and found that there are three options in Changsha: COVID-19 vaccine (Vero), COVID-19 vaccine (adenovirus vector) and recombinant COVID-19 vaccine (CHO). Among them, the COVID-19 vaccine (Vero) does not include details of the manufacturer.
The reporter contacted a community health service center in Jing'an District, Shanghai, and the staff said that there was no new coronavirus vaccine from Sinovac available for injection here, but there was a new coronavirus vaccine produced by another manufacturer that could be injected. However, because the vaccine is not specific to the latest strain, it is recommended that citizens in need go to other community health service centers and choose the XBB vaccine.
According to previous reports by Xinhua News Agency, the Beijing Center for Disease Control and Prevention stated on December 11 that winter and spring are seasons of high incidence of respiratory diseases, and multiple pathogens co-circulate. Currently, the main circulating strains of the new coronavirus are XBB and its sub-branches. In order to cope with the infection situation this winter and next spring, Beijing has recently launched the implementation of new coronavirus vaccinations containing XBB variant antigen components for key groups such as the elderly.
According to the Daily Economic News, a number of XBB vaccines have been approved for emergency use in my country. In June 2023, Chengdu Wesker's recombinant trivalent new coronavirus (XBB+BA.5+Delta variant) trimer protein vaccine was included in emergency use within a certain range. Entering December, companies such as China Cell, CanSino, and Livzon Group have also successively issued announcements that the new crown vaccine has been included in emergency use.